What is Chelation Therapy?
Chelation therapy is a medical treatment that uses specialized medications (iron chelators) to bind and remove excess iron from the body in patients with transfusion-dependent thalassemia, preventing life-threatening organ damage, particularly to the heart, liver, and endocrine organs. 1
Why Chelation is Necessary
- Each unit of transfused blood contains approximately 200 mg of iron, which accumulates in the body because humans lack a natural mechanism to excrete excess iron 1
- Without chelation, iron deposits in vital organs causing oxidative stress, cellular damage, and organ failure 2
- Heart disease has been the predominant cause of death in β-thalassemia major, making iron removal from cardiac tissue critical for survival 1
- Morbidity and mortality in thalassemia major are directly linked to the adequacy of chelation therapy 3, 4
Available Iron Chelators
Three chelators are commercially available, each with distinct properties 4, 5:
Deferoxamine
- Administered via continuous intravenous or subcutaneous infusion 1
- Requires 24-hour continuous infusion for acute heart failure (50 mg/kg/day) 1
- Most established chelator with longest track record 6
Deferiprone
- Oral medication given at 75 mg/kg/day in 3 divided doses 1
- Superior efficacy for cardiac iron removal compared to deferoxamine 1
- Often combined with deferoxamine for intensive chelation 1, 4
Deferasirox
- Once-daily oral chelator 7
- Equivalent efficacy to deferoxamine for overall iron removal 1
- Should be avoided in acute heart failure with marginal renal perfusion 1
- Associated with lowest TSH levels and best thyroid protection among chelators 8
How Chelation Works
- Chelators bind to free iron in the bloodstream and tissues, forming stable complexes that can be excreted through urine or feces 5
- The therapy removes accumulated iron and detoxifies reactive iron species, preventing and reversing iron-mediated organ injury 4
- Cardiac iron is removed very slowly, requiring several years of continuous treatment even with intensive chelation 1
Clinical Impact
The introduction of oral chelators has transformed thalassemia management, with real-world data showing mean decrease in liver iron concentration of 0.24 mg/g dry weight per year and mean increase in cardiac T2 of 1.68 ms per year after starting oral chelation.* 7
- Significant reduction in cardiac mortality has occurred since 2001 with improved chelation strategies and MRI monitoring 1
- In acute heart failure, survival improved from 50% at 1 year historically to 17 of 20 patients surviving with intensive deferoxamine treatment 1
- Combination therapy (deferoxamine plus deferiprone) shows superior efficacy for severe iron overload 1, 6
Monitoring Requirements
- Regular assessment of liver iron concentration and cardiac T2* by MRI is essential for tailoring chelation therapy 1
- Serum ferritin levels guide dose adjustments, though they correlate strongly with thyroid dysfunction (r = 0.94) 8
- Hepatic and renal function must be monitored, as chelation preserves organ function when properly managed 8
Critical Pitfalls
- Inadequate chelation continues to contribute to preventable morbidity and mortality 3
- Poor adherence is the most common cause of treatment failure—adherence is essential for long-term survival 1, 6
- Delay in starting appropriate chelation in acute heart failure can be life-threatening and requires immediate 24-hour continuous intravenous deferoxamine 1
- Deferasirox may be ill-advised in acute settings with compromised renal perfusion 1